Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Glioblastoma: Update Bulletin #2 [August 2018]

Product Code:
596200989
Publication Date:
August 2018
Format:
PDF
Price:
£910

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the glioblastoma multiforme (GBM) market. KOLs gave their candid insights on the following events: Mustang Bio announcing the publication of preclinical data demonstrating that GBM-targeted CD4+ CAR-T cells mediate superior antitumour activity over CD8+ CAR-T cells; MediciNova announcing that the Investigational New Drug (IND) application for MN-166 (ibudilast) for the treatment of GBM had been accepted and is now open with the US Food and Drug Administration (FDA); and Inovio Pharmaceuticals announcing that the first patient had been dosed as part of its Phase I/II immuno-oncology trial in patients with newly diagnosed GBM. 

Business Questions:

• Are KOLs excited by the prospect of using CAR-T therapies in the treatment of GBM?
• Does the lack of data prevent experts predicting if CD4+ IL13Rα2-CAR-T cells will be effective as a treatment for GBM?
• Does IL-13Rα2 make a good target for the treatment of GBM?
• What concerns do experts have in relation to the use, safety, cost and manufacturing of CAR-T therapies for GBM?
• Do KOLs believe MN-166 (ibudilast) has potential as a treatment for GBM?
• Does targeting phosphodiesterase make any sense as a treatment approach for GBM?
• Do experts have any safety concerns with MN-166?
• Are KOLs optimistic about Inovio’s T-cell activation/PD-1 inhibitor approach?
• What do KOLs think about the design of Inovio’s Phase I/II study?
• What type of data are KOLs hopeful that the study will provide?
• Are KOLs in agreement about the potential safety of Inovio’s regimen, or do concerns linger?
• How much emphasis are KOLs putting on the non-clinical data for Inovio’s regimen?
• Will newly diagnosed patients with GBM be the main focus for Inovio’s regimen?
• Do KOLs believe that T-cell generating therapies combined with PD-1 inhibitors will play a role in the future treatment of GBM?





customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved